Cidara Therapeutics, Inc. (CDTX) Financials
Stock symbol CDTX is outdated, potentially delisted? Maybe it is available on other exchange?
CDTX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| Sept. 30, 2024 | 162.3 million | 46.7 million |
| June 30, 2024 | 173.4 million | 42.4 million |
| March 31, 2024 | 52.7 million | 70.5 million |
| Dec. 31, 2023 | 68.5 million | 76.7 million |
CDTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| Sept. 30, 2024 | -36.8 million | 751000 |
| June 30, 2024 | -103.8 million | 703000 |
| March 31, 2024 | -6.7 million | 795000 |
| Dec. 31, 2023 | -12.9 million | 830000 |
CDTX Net Income
No data available :(
CDTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| Sept. 30, 2024 | 127.4 million | 2.4 million | - |
| June 30, 2024 | 164.4 million | 2.8 million | 4.3 million |
| March 31, 2024 | 29.0 million | 3.2 million | 4.6 million |
| Dec. 31, 2023 | 35.8 million | 3.6 million | 4.9 million |
CDTX Shares Outstanding
CDTX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| Sept. 30, 2024 | 106000 | 12.4 million | 5.0 million | - |
| June 30, 2024 | - | 6.7 million | 4.7 million | -57000 |
| March 31, 2024 | 23000 | 11.6 million | 6.0 million | - |
| Dec. 31, 2023 | 178000 | 15.4 million | 7.2 million | - |
CDTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| Sept. 30, 2024 | - | - |
| June 30, 2024 | 302000 | 57000 |
| March 31, 2024 | 8.5 million | 1.6 million |
| Dec. 31, 2023 | 17.6 million | 1.1 million |
CDTX Revenue by Segment
Graph available only for paid members. Upgrade to see it.
CDTX
Price: $221.38
52 week price:
Earnings Per Share: -11.21 USD
P/E Ratio: -19.72
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 3.0 million
Ebitda: -12.1 millionMarket Capitalization: 5.6 billion